Zusammenfassung
Die allgemeinen Regelungen für die Teilnahme am Straßenverkehr in der Bundesrepublik Deutschland sind in der Fahrerlaubnisverordnung (FeV) festgelegt. Für einen behandelnden Arzt besteht Aufklärungspflicht über die fehlende Fahreignung eines Patienten in seinem medizinischen Fachgebiet. Diese Aufklärung ist zu dokumentieren. Zusätzlich zu den gesetzlichen Vorgaben der FeV wird die Fahreignung bei Erkrankungen des Herz-Kreislauf-Systems in den Begutachtungsleitlinien zur Kraftfahrereignung des Gemeinsamen Beirats für Verkehrsmedizin behandelt. Da die FeV nur auf wenige kardiovaskuläre Erkrankungen eingeht und die Begutachtungsleitlinie nicht mehr dem aktuellen Stand des medizinischen Wissens entspricht, wurde im Auftrag der Deutschen Gesellschaft für Kardiologie das Positionspapier „Fahreignung bei kardiovaskulären Erkrankungen“ erstellt. Dieses Positionspapier beschreibt unter Berücksichtigung des aktuellen Wissenstandes die Bedingungen, wann bei Herzrhythmusstörungen, Synkopen, koronarer Herzerkrankung, Herzinsuffizienz und arterieller Hypertonie zeitlich begrenzt oder dauerhaft keine Fahreignung vorliegt.
Abstract
The general rules governing participation in road traffic in Germany are defined in the driver’s license law. Attending physicians are obligated to determine if a patient lacks the ability to drive from the perspective of their medical specialty. This assessment must be documented. In addition to the legal requirements laid down in the driver’s license law, the driving ability of patients with cardiovascular diseases is covered in the guideline on expert opinions appraising driving capability as specified by the Advisory Board for Traffic Medicine. Since the driver’s license law only addresses a few cardiovascular disorders and the guideline on expert opinions no longer reflects the current standard of medical knowledge, a position paper on fitness to drive and cardiovascular diseases was formulated on behalf of the German Cardiac Society. Taking the current level of knowledge into consideration, this position paper describes the conditions when cardiac arrhythmias, syncopes, coronary heart disease, cardiac insufficiency, and arterial hypertension represent grounds for establishing temporary or permanent inability to drive.
Literatur
Lewrenz H, Jagow FJ, Eggersmann A et al (2000) Bundesanstalt für Straßenwesen: Begutachtungsleitlinien zur Kraftfahrereignung. Berichte der Bundesanstalt für Straßenwesen, Mensch und Sicherheit, Heft M 115, Wirtschaftsverlag NW, Verlag für neue Wissenschaft GmbH, Postfach 101110, 27511 Bremerhaven
Bundesministerium der Justiz (2009) Verordnung über die Zulassung von Personen zum Straßenverkehr (Fahrerlaubnisverordnung – FeV, 1.09.2009). http://bundesrecht.juris.de/fev/BJNR221410998.html
Petch MC (on behalf of the task force, 1998) Driving and heart disease. Eur Heart J 19:1165–1177
Simpson C, Dorian P, Gupta A et al (2004) Assessment of the cardiac patient for fitness to drive: Drive subgroup executive summary. Can J Cardiol 20:1314–1320. Die kompletten Ausführungen sind im Internet unter http://www.ccs.ca erhältlich
Öström M, Eriksson A (1987) Natural death while driving. J Forensic Sci 32:988–998
Cantor WJ, Fitchett D, Borgundvaag B et al (2009) For the TRANSFER-AMI trial investigators routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360:2705–2718
Müller D, Agrawal R, Arntz H-R (2006) How sudden is sudden cardiac death? Circulation 114:1146–1150
Kubitzki J, Janitzek T (2009) Sicherheit und Mobilität älterer Verkehrteilnehmer. Allianz Deutschland AG, Fritz-Schäffer-Str. 9, D-81737 München, Deutschland
Wood KA, Drew BJ, Scheinman MM (1997) Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 79:145–149
Clague JR, Dagres N, Kottkamp H et al (2001) Targeting the slow pathway for atrioventricular nodal reentrant tachycardia: initial results and longterm follow-up in 379 consecutive patients. Eur Heart J 22:82–88
Klein GJ, Bashore TM, Sellers TD et al (1979) Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 301:1080–1085
Munger TM, Packer DL, Hammill SC et al (1993) A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota 1953–1989. Circulation 87:866–873
Pietersen AH, Damgaard Andersen E, Sandoe E (1992) Atrial fibrillation in the Wolff-Parkinson-White syndrome. Am J Cardiol 70:38A–43A
Antz M, Weiss C, Volkmer M et al (2002) Risk of sudden death after successful accessory atrioventricular pathway ablation in resuscitated patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 13:231–236
Kose S, Amasyali B, Aytemir K et al (2005) Radiofrequency catheter ablation of accessory pathways during pre-excited atrial fibrillation: acute success rate and long-term clinical follow-up results as compared to those patients undergoing successful catheter ablation during sinus rhythms. Heart Vessels 20:142–146
Rybak K, Nowak B, Pfeiffer D et al (2008) Kommentar zu den ESC-Leitlinien „Guidelines for cardiac pacing and cardiac resynchronization therapy“. Kardiologe 2:463–478
Tang ASL, Roberts RS, Kerr C et al (2001) Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. Circulation 103:3081–3085
Connolly SJ, Kerr CR, Gent M et al (2000) Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med 342:1385–1391
Maisel WH (2006) Pacemaker and ICD generator reliability. JAMA 295:1929–1934
Hauser RG, Hayes DL, Kallinen LM et al (2007) Clinical experience with pacemaker pulse generators and transvenous leads: an 8-year prospective multicenter study. Heart Rhythm 4:154–160
Pavlovic SU, Kocovic D, Djordjevic M et al (1991) The etiology of syncope in pacemaker patients. PACE 14:2086–2091
Sgarbossa EB, Pinski SL, Jaeger FJ et al (1992) Incidence and predictors of syncope in paced patients with sick sinus syndrome. PACE 15 Part II:2055–2060
Platt S, Furman S, Gross JN et al (1996) Transtelephone monitoring for pacemaker follow-up 1981–1994. PACE 19:2089–2098
Wiegand UK, Bode F, Bonnemeier H et al (2003) Long-term complication rates in ventricular, single lead VDD, and dual chamber pacing. PACE 26:1961–1969
Moya A für die task force for the diagnosis and management of syncope of the European Society of Cardiology (ESC) (2009) Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 30:2631–2671
Gardner RA, Kruyer WB, Pickard JS, Celio PV (2000) Nonsustained ventricular tachycardia in 193 U.S. military aviators: long-term follow up. Aviat Space Environ Med 71:783–790
Altemose GT, Buxton AE (1999) Idiopathic ventricular tachycardia. Annu Rev Med 50:159–177
Epstein AE für die Task Force ACC/AHA/HRS (2008) Guidelines for device-based therapy of cardiac rhythm abnormalities. Circulation 117:e350–e408 (http://circ.ahajournals.org/cgi/content/full/circulationaha;120/5/e34)
Frolkis JP, Pothier CE, Blackstone EH, Lauer MS (2003) Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 348:781–790
Buxton AE, Lee KL, DiCarlo L et al (2000) Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 342:1937–1945
Gomes JA, Hariman RI, Kang PS et al (1984) Programmed electrical stimulation in patients with high-grade ventricular ectopy: electrophysiologic findings and prognosis for survival. Circulation 70:43–51
Della Bella P, De Ponti R, Uriarte JAS et al (2002) Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia. Eur Heart J 23:414–424
Grimm W, Christ M, Bach J et al (2003) Noninvasive arrhtyhmia risk stratification in idiopathic dilated cardiomypathy. Results of the Marburg Cardiomyopathy Study. Circulation 108:2883–2891
Kadish A, Dyer A, Daubert JP et al (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomypathy. N Engl J Med 350:2151–2158
Jung W, Lüderitz B (1996) Quality of life and driving in recipients of the implantable cardioverter-defibrillator. Am J Cardiol 78:51–56
Vijgen J, Botto G, Camm J et al (2009) Consensus statement of the European heart rhythm association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Europace 11:1097–1107
Böcker D, Block M, Isbruch F et al (1995) Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J 73:158–163
Freedberg NA, Hill JM, Fogel RI, Prystowsky EN (2001) Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter-defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restriction. CARE group. J Am Coll Cardiol 37:1910–1915
Kou WH, Calkins H, Lewis R et al (1991) Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Int Med 115:942–945)
Bänsch D, Brunn J, Castrucci M et al (1998) Syncope in patients with an implantable cardioverter-defibrillator: incidence, perdiction and implications for driving restrictions. J Am Coll Cardiol 31:608–615
Albert CM, Rosenthal L, Calkins H et al (2007) Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias. J Am Coll Cardiol 50:2233–2240
Conti JB, Woodard DA, Tucker KJ et al (1997) Modification of patient driving behavior after implantation of a cardioverter defibrillator. Pacing Clin Electrophysiol 20:2200–2204
Curtis AB, Conti JB, Tucker KJ et al (1995) Motor vehicle accidents in patients with an implantable cardioverter-defibrillator. J Am Coll Cardiol 26:180–184
Trappe HJ, Wenzlaff P, Grellman G (1998) Should patients with implantable cardioverter defibrillators be allowed to drive? Observations in 291 patients from a single center over an 11-year period. J Interv Card Electrophysiol 2:193–201
Akiyama T, Powell JL, Mitchell LB et al (2001) Resumption of driving after life-threatining ventricular tachyarrhythmias. N Engl J Med 345:391–397
Larsen GC, Stupey MR, Walance CG et al (1994) Recurrent cardiac events in survivors of ventricular fibrillation or tachykardia. Implications for driving restrictions. JAMA 271:135–139
Grubb BP (2007) Driving and implantable cardioverter-defibrillators. A clearer view. J Am Coll Cardiol 50:2241–2242
Moss AJ, Hall WJ, Cannom DS et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335:1933–1940
Buxton AE, Lee KL, Fisher JD et al (1999) A randomizied study for the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341:1882–1890
Moss AJ, Zareba W, Hall WJ et al (2002) Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883
Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237
Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac-resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150
Packer DL, Prutkin JM, Hellkamp AS et al (2009) Impact of implantable cardioverter-defibrillator, Amiodaron, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 120:2170–2176
Epstein AE, Baessler CA, Curtis AB et al (2007) Addendum to „Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology.“ Public safety issues in patients with implantable defibrillators. A scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation 115:1170–1176
Soteriades ES, Evans JC, Larson MG et al (2002) Incidence and prognosis of syncope. N Engl J Med 347:878–885
Constantino G, Perego F, Dipaola F et al (2008) Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the StePS (Short-Term Prognosis of Syncope) study. J Am Coll Cardiol 51:276–283
Sorajja D, Nesbitt GC, Hodge DO et al (2009) Syncope while driving. Clinical characteristics, causes, and prognosis. Circulation 120:928–934
Kushner JA, Kou WH, Kadish AH, Morady F (1989) Natural history with unexplained syncope and nondiagnostic electrophysiologic study. J Am Coll Cardiol 14:391–396
Sud S, Klein GJ, Skanes AC et al (2009) Predicting the cause of syncope from clinical history in patients undergoing prolonged monitoring. Heart Rhythm 6:238–243
Werf F van der for the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Hear J 29:2909–2945
Bassand J-P for the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660
Thygesen K, Alpert JS, White HD on behalf of the joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction (2007) Universal definition of myocardial infarction. Eur Heart J 28:2525–2538
Fox KA, Dabbous OH, Goldberg RJ et al (2006) Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). B Med J 333:1091–1094
Poole-Wilson A, Pocock SJ, Fox KAA et al (2006) Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial. Heart 92:1473–1479
Solomon SD, Zelenkofske S, McMurray JJV et al (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352:2581–2588
Adabag AS, Therneau TM, Gersh BJ et al (2008) Sudden death after myocardial infarction. JAMA 300:2022–2029
Hsia J, Jablonski KA, Rice MM et al (2008) Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. Am J Cardiol 101:457–461
Spaulding C, Daemen J, Boersma E et al (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989–997
Goldenberg I, Jonas M, Tenenbaum A et al (2003) Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med 163:2301–2305
Daemen J, Wenaweser P, Tsuchida K et al (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678
Pinto RP, Romerill DB, Nasser WK et al (1996) Prognosis of patients with frequent premature ventricular complexes and nonsustained ventricular tachycardia after coronary artery bypass graft surgery. Clin Cardiol 19:321–324
Vickrey BG, Rector TS, Wickstrom SL et al (2002) Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 33:901–906
Davies RR, Goldstein LJ, Coady MA et al (2002) Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 73:17–27
Davies RR, Kaple RK, Mandapati D et al (2007) Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg 83:1338–1344
Lederle FA (2009) The natural history of abdominal aortic aneurysm. Acta Chir Belg 109:7–12
Levy WC, Mozaffarian D, Linker DT et al (2006) The seattle heart failure model, predicition of survival in heart failure. Circulation 113:1424–1433
Mozaffarian D, Anker SD, Anand I et al (2007) Prediction of mode of death in heart failure, the seattle heart failure model. Circulation 116:392–398
Connolly SJ, Hallstrom AP, Cappato R et al (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 21:2071–2078
Owan TE, Hodge DO, Herges RM et al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259
Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467
Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362:777–781
Uretzky BF, Kormos RL, Zerbe TR et al (1992) Cardiac events after heart transplantation: incidence and predictive value of coronary arteriography. J Heart Lung Transplant 11:S45–51
McGiffin DC, Naftel DC, Spann JL et al (1998) Risk of death or incapacitation after heart transplantation, with particular reference to pilots. J Heart Lung Transplant 17:497–504
Maron BJ, Casey SA, Poliac LC et al (1999) Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281:650–655
Spirito P, Autore C, Rapezzi C et al (2009) syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119:1703–1710
Ammash NM, Seward JB, Bailey KR et al (2000) Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101:2490–2496
Brugada J, Brugada R, Brugada P (2003) Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 108:3092–3096
Hobbs JB, Peterson DR, Moss AJ et al (2006) Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 296:1249–1254
Hulot JS, Jouven X, Empana JP et al (2004) Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 110:1879–1884
Chizner MA, Pearle DL, Leon AC de (1980) The natural history of aortic stenosis in adults. Am Heart J 99:419–424
Kitiyakara C, Guzman NJ (1998) Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol 9:133–142
Faulhaber H-D, Bansi D (1985) Begutachtung der Fahrtauglichkeit bei arterieller Hypertonie. Z Ärztl. Fortbild 79:755–757
Erbel R, Lüderitz B (1999) Fahrerlaubnis aus Sicht des Kardiologen, Z Kardiol 88:154–161
Epstein AE, Miles WM, Benditt DG et al (1996) Personal and public safety issues related to arrhythmias that may affect consciousness:implications for regulation and physician recommendations. Circulation 94:1147–1166
Vardas PE (für die Mitglieder der Task Force) (2007) Guidelines for cardiac pacing and cardiac resynchronisation therapy. Europace 9:959–998
Blumenthal R, Braunstein J, Connolly H et al (2002) Cardiovascular advisory panel guidelines for the medical examination of commercial motor vehicle drivers. US department of transportation, federal motor carrier safety administration. Report No. FMCSA-MCP-02–002. Abrufbar unter http://www.fmcsa.dot.gov/documents/cardio.pdf
Garrahy P, McAlister H, Hossack K (2002) Cardiovascular disease and driving. http://www.csanz.edu.au/guidelines/practice/Drivegl/2002.pdf
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Klein, H., Krämer, A., Pieske, B. et al. Fahreignung bei kardiovaskulären Erkrankungen. Kardiologe 4, 441–473 (2010). https://doi.org/10.1007/s12181-010-0308-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12181-010-0308-9